{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:01:40Z","timestamp":1790251300181,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003200","name":"MOSTI","doi-asserted-by":"publisher","award":["06-02-12-SF0314"],"award-info":[{"award-number":["06-02-12-SF0314"]}],"id":[{"id":"10.13039\/501100003200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2019.05.083","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T07:31:17Z","timestamp":1559979077000},"page":"3989-4000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Vaccination challenges and strategies against long-lived Toxoplasma gondii"],"prefix":"10.1016","volume":"37","author":[{"given":"Fei-Kean","family":"Loh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2132-2346","authenticated-orcid":false,"given":"Sheila","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sek-Chuen","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-5697","authenticated-orcid":false,"given":"Chee-Mun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.05.083_b0005","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/infdis\/172.6.1561","article-title":"Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease","volume":"172","author":"Howe","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.083_b0010","first-page":"185","article-title":"Recent observations on the biology of Toxoplasma gondii","volume":"86","author":"Hutchinson","year":"1966","journal-title":"Trans Ophthalmol Soc UK"},{"key":"10.1016\/j.vaccine.2019.05.083_b0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/expr.1994.1039","article-title":"Experimental induction of bradyzoite-specific antigen expression and Cyst formation by the RH strain of Toxoplasma gondii in vitro","volume":"78","author":"Soete","year":"1994","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0020","doi-asserted-by":"crossref","unstructured":"Soete M, Fortier B, Camus D, Dubremetz JF. Toxoplasma Gondii: patterns of bradyzoite-tachyzoite interconversion in vitro. In: Smith JE, editor. Toxoplasmosis, Berlin, Heidelberg: Springer Berlin Heidelberg; 1993. p. 93\u20138. 10.1007\/978-3-642-78559-7_10.","DOI":"10.1007\/978-3-642-78559-7_10"},{"key":"10.1016\/j.vaccine.2019.05.083_b0025","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1471-4922(02)02248-1","article-title":"Toxoplasma gondii tachyzoite-bradyzoite interconversion","volume":"18","author":"Lyons","year":"2002","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0030","first-page":"167","article-title":"Ultrastructural study of early stages of asexual multiplication and microgametogony of Toxoplasma gondii in the small intestine of the cat","volume":"82B","author":"Ferguson","year":"2009","journal-title":"Acta Pathol Microbiol Scand Sect B Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0035","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ijpara.2008.03.007","article-title":"Toxoplasma gondii infection in humans and animals in the United States","volume":"38","author":"Dubey","year":"2008","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090203","article-title":"Toxoplasmosis - a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries","volume":"9","author":"Flegr","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.05.083_b0045","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2352-3018(17)30005-X","article-title":"Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2019.05.083_b0050","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jped.2016.02.014","article-title":"Evaluation of the Western blotting method for the diagnosis of congenital toxoplasmosis","volume":"92","author":"Capobiango","year":"2016","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.vaccine.2019.05.083_b0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/acps.12423","article-title":"Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis","volume":"132","author":"Sutterland","year":"2015","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.vaccine.2019.05.083_b0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jad.2016.11.016","article-title":"Is there any association between Toxoplasma gondii infection and bipolar disorder? A systematic review and meta-analysis","volume":"209","author":"de Barros","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.vaccine.2019.05.083_b0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fmicb.2017.00025","article-title":"A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006\u20132016)","volume":"8","author":"Montazeri","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0070","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00057-17","article-title":"Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice","volume":"31","author":"Dunay","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2019.05.083_b0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40588-016-0045-3","article-title":"Reexamining chronic Toxoplasma gondii infection: surprising activity for a \u2018Dormant\u2019 parasite","volume":"3","author":"Sinai","year":"2016","journal-title":"Curr Clin Microbiol Reports"},{"key":"10.1016\/j.vaccine.2019.05.083_b0080","article-title":"Current progress toward vaccines against Toxoplasma gondii","volume":"23","author":"Garcia","year":"2014","journal-title":"Vaccine Dev Ther"},{"key":"10.1016\/j.vaccine.2019.05.083_b0085","doi-asserted-by":"crossref","unstructured":"Buxton D, Innes Ea. A commercial vaccine for ovine toxoplasmosis. Parasitology 1995;110 Suppl:S11\u20136. 10.1017\/S003118200000144X.","DOI":"10.1017\/S003118200000144X"},{"key":"10.1016\/j.vaccine.2019.05.083_b0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0065-308X(08)60152-9","article-title":"DNA vaccines: technology and application as anti-parasite and anti-microbial agents","volume":"42","author":"Alarcon","year":"1999","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0095","doi-asserted-by":"crossref","unstructured":"Li XZ, Wang XH, Xia LJ, Weng YB, Hernandez Ja, Tu LQ, et al. Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice. BMC Infect Dis 2015;15:114. 10.1186\/s12879-015-0815-1.","DOI":"10.1186\/s12879-015-0815-1"},{"key":"10.1016\/j.vaccine.2019.05.083_b0100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.meegid.2016.10.006","article-title":"Recombinant canine adenovirus type-2 expressing TgROP16 provides partial protection against acute Toxoplasma gondii infection in mice","volume":"45","author":"Li","year":"2016","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1051\/parasite\/2017013","article-title":"Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes","volume":"24","author":"Wang","year":"2017","journal-title":"Parasite"},{"key":"10.1016\/j.vaccine.2019.05.083_b0110","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2019.05.083_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.00605","article-title":"Induction of protective immunity against Toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP)","volume":"8","author":"Luo","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2019.05.083_b0125","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem Sci"},{"key":"10.1016\/j.vaccine.2019.05.083_b0130","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1007\/s00436-015-4652-3","article-title":"A long-lasting protective immunity against chronic toxoplasmosis in mice induced by recombinant rhoptry proteins encapsulated in poly (lactide-co-glycolide) microparticles","volume":"114","author":"Xu","year":"2015","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2019.05.083_b0135","first-page":"1","article-title":"Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactide-co-glycolide) microspheres induces long-term protective immunity in mice","author":"Zhang","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.083_b0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.biomaterials.2015.01.056","article-title":"Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection","volume":"50","author":"Dimier-Poisson","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.vaccine.2019.05.083_b0145","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1128\/IAI.00649-09","article-title":"Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL\/6 mice by immunization with an attenuated type I vaccine strain","volume":"77","author":"Gigley","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.05.083_b0150","doi-asserted-by":"crossref","unstructured":"Gigley JP, Fox Ba, Bzik DJ. Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication. J Immunol 2009;182:1069\u201378. 10.4049\/jimmunol.182.2.1069.","DOI":"10.4049\/jimmunol.182.2.1069"},{"key":"10.1016\/j.vaccine.2019.05.083_b0155","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1128\/EC.00297-10","article-title":"Type II Toxoplasma gondii KU80 knockout strains enable functional analysis of genes required for Cyst development and latent infection","volume":"10","author":"Fox","year":"2011","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.vaccine.2019.05.083_b0160","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1128\/IAI.02756-14","article-title":"Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection","volume":"83","author":"Fox","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.05.083_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173745","article-title":"Abd Ellah MR, Bzik DJ, Igarashi M. Lactate dehydrogenase in Toxoplasma gondii controls virulence, bradyzoite differentiation, and chronic infection","volume":"12","author":"Abdelbaset","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.05.083_b0170","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/IAI.02606-14","article-title":"AMA1-deficient Toxoplasma gondii parasites transiently colonize mice and trigger an innate immune response that leads to long-lasting protective immunity","volume":"83","author":"Lagal","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.05.083_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00730","article-title":"Immunization with Toxoplasma gondii GRA17 deletion mutant induces partial protection and survival in challenged mice","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0180","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/infdis\/jiy211","article-title":"Live attenuated Pru:\u0394cdpk2 strain of Toxoplasma gondii protects against acute, chronic, and congenital toxoplasmosis","volume":"218","author":"Wang","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.083_b0185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/00480169.1988.35489","article-title":"Toxoplasmosis in sheep further evaluation of the ability of a live toxoplasma gondii vaccine to prevent lamb losses and reduce congenital infection following experimental oral challenge","volume":"36","author":"Wilkins","year":"1988","journal-title":"N Z Vet J"},{"key":"10.1016\/j.vaccine.2019.05.083_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1051\/vetres\/2010021","article-title":"knockout Toxoplasma gondii is a good candidate for a vaccine against T. gondii -induced abortion in sheep","volume":"41","author":"M\u00e9v\u00e9lec","year":"2010","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2019.05.083_b0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0264-410X(92)90420-O","article-title":"Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine","volume":"10","author":"Chatfield","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.083_b0200","doi-asserted-by":"crossref","unstructured":"Zorgi NE, Costa A, Galisteo AJ, do Nascimento N, De Andrade HF. Humoral responses and immune protection in mice immunized with irradiated T. gondii tachyzoites and challenged with three genetically distinct strains of T. gondii. Immunol Lett 2011;138:187\u201396. 10.1016\/j.imlet.2011.04.007.","DOI":"10.1016\/j.imlet.2011.04.007"},{"key":"10.1016\/j.vaccine.2019.05.083_b0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12879-016-2104-z","article-title":"Protection via a ROM4 DNA vaccine and peptide against Toxoplasma gondii in BALB\/c mice","volume":"17","author":"Han","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.083_b0210","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1110\/ps.041059505","article-title":"Benchmarking B cell epitope prediction: underperformance of existing methods","volume":"14","author":"Blythe","year":"2005","journal-title":"Protein Sci"},{"key":"10.1016\/j.vaccine.2019.05.083_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003001","article-title":"Vaccines from empirical development to rational design","volume":"8","author":"Rueckert","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2019.05.083_b0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-016-2147-1","article-title":"Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii","volume":"17","author":"Song","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.083_b0225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2105-8-361","article-title":"Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines","volume":"8","author":"Bui","year":"2007","journal-title":"BMC Bioinf"},{"key":"10.1016\/j.vaccine.2019.05.083_b0230","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/IAI.00703-09","article-title":"Protection against lethal Neospora caninum infection in mice induced by heterologous vaccination with a mic1 mic3 knockout Toxoplasma gondii strain","volume":"78","author":"Penarete-Vargas","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.05.083_b0235","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1007\/s00436-015-4609-6","article-title":"MIC3, a novel cross-protective antigen expressed in Toxoplasma gondii and Neospora caninum","volume":"114","author":"Yang","year":"2015","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2019.05.083_b0240","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1073\/pnas.90.10.4455","article-title":"In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment","volume":"90","author":"Cheng","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.05.083_b0245","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.virol.2005.08.040","article-title":"DNA immunization using a non-viral promoter","volume":"344","author":"Vanniasinkam","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.05.083_b0250","doi-asserted-by":"crossref","DOI":"10.1590\/S0100-879X1999000200003","article-title":"Regulation of transgene expression in genetic immunization","volume":"32","author":"Harms","year":"1999","journal-title":"Brazil J Med Biol Res"},{"key":"10.1016\/j.vaccine.2019.05.083_b0255","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1006\/mthe.2001.0318","article-title":"TNF\u03b1 and IFN\u03b3 induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression","volume":"3","author":"Sung","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2019.05.083_b0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4161\/hv.22474","article-title":"Development of toxoplasma gondii vaccine A global challenge","volume":"9","author":"Verma","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2019.05.083_b0265","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1590\/S0074-02762009000200027","article-title":"Treating ocular toxoplasmosis - current evidence","volume":"104","author":"Stanford","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2019.05.083_b0270","doi-asserted-by":"crossref","unstructured":"Suhrbier A. Multi-epitope DNA vaccines. Immunol Cell Biol 1997;75:402\u20138. 10.1038\/icb.1997.63.","DOI":"10.1038\/icb.1997.63"},{"key":"10.1016\/j.vaccine.2019.05.083_b0275","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-3024.2005.00738.x","article-title":"Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii","volume":"27","author":"Cong","year":"2005","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0280","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1756-3305-7-145","article-title":"Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice","volume":"7","author":"Cong","year":"2014","journal-title":"Parasit Vect"},{"key":"10.1016\/j.vaccine.2019.05.083_b0285","doi-asserted-by":"crossref","unstructured":"Gedik Y, G\u00fcl\u00e7e Iz S, Can H, De\u0287irmenci D\u00f6\u015fkaya A, Ismet Delilo\u0287lu G\u00fcrhan S, G\u00fcr\u00fcz Y, et al. Immunogenic multistage recombinant protein vaccine confers partial protection against experimental toxoplasmosis mimicking natural infection in murine model. Trials Vaccinol 2016;5:15\u201323. 10.1016\/j.trivac.2015.11.002.","DOI":"10.1016\/j.trivac.2015.11.002"},{"key":"10.1016\/j.vaccine.2019.05.083_b0290","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.actatropica.2015.07.013","article-title":"Homologous prime-boost strategy with TgPI-1 improves the immune response and protects highly susceptible mice against chronic Toxoplasma gondii infection","volume":"150","author":"S\u00e1nchez","year":"2015","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2019.05.083_b0295","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.exppara.2018.04.003","article-title":"Immuno-efficacy of DNA vaccines encoding PLP1 and ROP18 against experimental Toxoplasma gondii infection in mice","volume":"188","author":"Chen","year":"2018","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0300","first-page":"1","article-title":"Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route","author":"Rashid","year":"2016","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0305","doi-asserted-by":"crossref","first-page":"483-8-4","DOI":"10.1016\/0923-2494(92)80058-S","article-title":"Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity","volume":"143","author":"Gustafson","year":"1992","journal-title":"Res Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0310","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2019.05.083_b0315","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12639-014-0546-z","article-title":"The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice","volume":"40","author":"El Temsahy","year":"2016","journal-title":"J Parasit Dis"},{"key":"10.1016\/j.vaccine.2019.05.083_b0320","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5501\/wjv.v4.i3.156","article-title":"Novel antigen delivery systems","volume":"4","author":"Trovato","year":"2015","journal-title":"World J Virol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0325","doi-asserted-by":"crossref","first-page":"29379","DOI":"10.1038\/srep29379","article-title":"Transgenic Eimeria tenella as a vaccine vehicle: expressing TgSAG1 elicits protective immunity against Toxoplasma gondii infections in chickens and mice","volume":"6","author":"Tang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.05.083_b0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.actatropica.2016.08.025","article-title":"Cross-protection induced by Toxoplasma gondii virus-like particle vaccine upon intraperitoneal route challenge","volume":"164","author":"Lee","year":"2016","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2019.05.083_b0335","article-title":"Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.05.083_b0340","first-page":"1574","article-title":"Immune responses to adenovirus and adeno-associated virus in humans","volume":"6","author":"Chirmule","year":"1999","journal-title":"GeneTher"},{"key":"10.1016\/j.vaccine.2019.05.083_b0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.05.083_b0350","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.chom.2009.06.005","article-title":"Gut commensal bacteria direct a protective immune response against the human pathogen Toxoplasma gondii","volume":"6","author":"Benson","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2019.05.083_b0355","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jam.13446","article-title":"Lactic acid bacteria \u2014 promising vaccine vectors: possibilities, limitations, doubts","volume":"123","author":"Szatraj","year":"2017","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063201","article-title":"Recombinant Vaccines against T. gondii: Comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1","volume":"8","author":"Mendes","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.05.083_b0365","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.actatropica.2015.03.013","article-title":"Epitope analysis, expression and protection of SAG5A vaccine against Toxoplasma gondii","volume":"146","author":"Lu","year":"2015","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2019.05.083_b0370","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/s13071-015-1108-7","article-title":"A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB\/c mice against parasite infection","volume":"8","author":"Yin","year":"2015","journal-title":"Parasit Vect"},{"key":"10.1016\/j.vaccine.2019.05.083_b0375","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.083_b0380","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1517\/17425247.2015.1077559","article-title":"Nucleic acid vaccination strategies against infectious diseases","volume":"12","author":"Mar\u0107","year":"2015","journal-title":"Exp Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2019.05.083_b0385","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2796.2003.01140.x","article-title":"DNA vaccines: a review","volume":"253","author":"Liu","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2019.05.083_b0390","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1359-6446(00)01600-7","article-title":"Innovations in oral gene delivery: challenges and potentials","volume":"6","author":"Page","year":"2001","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.vaccine.2019.05.083_b0395","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/intimm\/dxu063","article-title":"Challenges in mucosal vaccines for the control of infectious diseases","volume":"26","author":"Azegami","year":"2014","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0400","doi-asserted-by":"crossref","unstructured":"EL-Malky MA, Al-Harthi SA, Mohamed RT, EL Bali MA, Saudy NS. Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: Comparison of immune responses in intranasal versus intramuscular administrations. Parasitol Res 2014;113:2277\u201384. 10.1007\/s00436-014-3882-0.","DOI":"10.1007\/s00436-014-3882-0"},{"key":"10.1016\/j.vaccine.2019.05.083_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00317","article-title":"Targeted delivery of Toxoplasma gondii antigens to dendritic cells promote immunogenicity and protective efficiency against toxoplasmosis","volume":"9","author":"Lakhrif","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0410","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.vetpar.2011.11.034","article-title":"Humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A","volume":"186","author":"da Cunha","year":"2012","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0415","first-page":"1","article-title":"Innate recognition of Toxoplasma gondii in humans involves a mechanism distinct from that utilized by rodents","author":"Sher","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0420","first-page":"732","article-title":"A gene(s) within the H-2D region determines the development of toxoplasmic encephalitis in mice","volume":"74","author":"Suzuki","year":"1991","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2019.05.083_b0425","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0165-5728(91)90040-E","article-title":"Toxoplasma encephalitis of immunocompetent and nude-mice - immunohistochemical characterization of toxoplasma antigen, infiltrates and major histocompatibility complex gene-products","volume":"31","author":"Schluter","year":"1991","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0430","first-page":"6615","article-title":"Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB\/c mice but not in CBA\/J Mice","volume":"71","author":"Letscher-bru","year":"2003","journal-title":"Society"},{"key":"10.1016\/j.vaccine.2019.05.083_b0435","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1007\/s00436-015-4701-y","article-title":"Towards vaccine against toxoplasmosis: evaluation of the immunogenic and protective activity of recombinant ROP5 and ROP18 Toxoplasma gondii proteins","volume":"114","author":"Grzybowski","year":"2015","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2019.05.083_b0440","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1590\/S0074-02762009000200019","article-title":"Vaccines against Toxoplasma gondii: challenges and opportunities","volume":"104","author":"Jongert","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2019.05.083_b0445","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.4049\/jimmunol.165.3.1498","article-title":"Human dendritic cells discriminate between viable and killed Toxoplasma gondii Tachyzoites: dendritic cell activation after infection with viable parasites results in CD28 and CD40 ligand signaling that controls IL-12-dependent and -independent T Cell Pro","volume":"165","author":"Subauste","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0450","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/eji.201445045","article-title":"Adaptive immune-mediated host resistance to Toxoplasma gondii is governed by the NF-kB regulator Bcl-3 in dendritic cells","volume":"45","author":"Tassi","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0455","article-title":"Toxoplasma gondii microneme proteins 1 and 4 bind to Toll-like receptors 2 and 4 N-glycans triggering innate immune response","author":"Sardinha-Silva","year":"2017","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2019.05.083_b0460","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/1471-2334-14-525","article-title":"Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondii rhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model","volume":"14","author":"Xu","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.083_b0465","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/1471-2334-14-487","article-title":"Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice","volume":"14","author":"Chen","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.083_b0470","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.exppara.2015.12.013","article-title":"Co-administration of interleukins 7 and 15 with DNA vaccine improves protective immunity against Toxoplasma gondii","volume":"162","author":"Chen","year":"2016","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0475","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.actatropica.2016.12.004","article-title":"Protective immune response in mice induced by a suicidal DNA vaccine encoding NTPase-II gene of Toxoplasma gondii","volume":"166","author":"Zheng","year":"2017","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2019.05.083_b0480","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1586\/14760584.2015.1061938","article-title":"Protective efficacy of two novel DNA vaccines expressing Toxoplasma gondii rhomboid 4 and rhomboid 5 proteins against acute and chronic toxoplasmosis in mice","volume":"14","author":"Zhang","year":"2015","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2019.05.083_b0485","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.parint.2017.06.002","article-title":"SAG5B and SAG5C combined vaccine protects mice against Toxoplasma gondii infection","volume":"66","author":"Lu","year":"2017","journal-title":"Parasitol Int"},{"key":"10.1016\/j.vaccine.2019.05.083_b0490","article-title":"Partial protective effect of intranasal immunization with recombinant toxoplasma gondii rhoptry protein 17 against toxoplasmosis in mice","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.05.083_b0495","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1051\/parasite\/2016012","article-title":"Recombinant Toxoplasma gondii phosphoglycerate mutase 2 confers protective immunity against toxoplasmosis in BALB\/c mice","volume":"23","author":"Wang","year":"2016","journal-title":"Parasite"},{"key":"10.1016\/j.vaccine.2019.05.083_b0500","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.vaccine.2014.01.095","article-title":"Vaccination with profilin encapsulated in oligomannose-coated liposomes induces significant protective immunity against Toxoplasma gondii","volume":"32","author":"Tanaka","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.083_b0505","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12865-016-0173-9","article-title":"Intranasal immunization with recombinant Toxoplasma gondii actin depolymerizing factor confers protective efficacy against toxoplasmosis in mice","volume":"17","author":"Liu","year":"2016","journal-title":"BMC Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0510","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.vaccine.2014.03.092","article-title":"Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice","volume":"32","author":"El Bissati","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.083_b0515","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.actatropica.2014.05.001","article-title":"Intranasal immunisation of the recombinant Toxoplasma gondii receptor for activated C kinase 1 partly protects mice against T. gondii infection","volume":"137","author":"Wang","year":"2014","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2019.05.083_b0520","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00430-015-0447-5","article-title":"do Nascimento N, de Andrade HF. Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites","volume":"205","author":"Zorgi","year":"2016","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2019.05.083_b0525","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.parint.2018.02.002","article-title":"Disodium cromoglycate may act as a novel adjuvant for UV-attenuated Toxoplasma gondii vaccine in mouse model","volume":"67","author":"Li","year":"2018","journal-title":"Parasitol Int"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:32:41Z","timestamp":1759401161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19307303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":105,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X19307303"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.083","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination challenges and strategies against long-lived Toxoplasma gondii","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}